Skip to main content
Premium Trial:

Request an Annual Quote

Bavaria Grants Kinaxo $900K for Chemical Proteomics

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies has received a grant of €575,000 ($906,000) from the Bavarian Ministry of Economic Affairs, Infrastructure, Transport, and Technology.
 
Kinaxo plans to use the money to expand the uses for its chemical proteomics technology for identifying protein targets of compounds found in cell-based drug screens.
 
Martinsried, Germany-based Kinaxo’s Cellular Target Profiling technology was originally developed by the Max Planck Institute of Biochemistry, from which Kinaxo is a spin-off.
 
"This funding will allow us to significantly expand the scope and utility of our chemical proteomics capability, helping to demonstrate further valuable applications for broad adoption in the field of small molecule drug development," Kinaxo CEO Andreas Jenne said in a statement.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.